EX-99.1 2 d167778dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company Watertown, Mass. (July 27, 2026) - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stages through commercialization and franchise expansion, helping bring important new medicines to patients around the world. In his role, Dr. Rooney will lead Kymera’s global clinical development strategy and guide the advancement of the Company’s oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, M…
Open exhibit ↗Current Report · Items 5.02, 7.01, 9.01 · 8-K
Kymera Therapeutics, Inc.
KYMRNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Jared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer (“CMO”) of Kymera Therapeutics, Inc. (the “Company”) and submitted his resignation on July 27, 2026. Dr.…
Company context
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.